Tau pathology is a hallmark of Alzheimer's disease (AD) but also occurs in normal cognitive
aging. Using the tau PET agent 18 F-AV-1451, we examined retention patterns in cognitively …

See Sarazin et al . (doi: 10.1093/brain/aww041 ) for a scientific commentary on this article.
The advent of the positron emission tomography tracer 18 F-AV1451 provides the unique …

Neuropathological and in vivo studies have revealed a tight relationship between tau
pathology and cognitive impairment across the Alzheimer’s disease spectrum. However, tau …

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer’s disease (AD) and are thought to play crucial roles in a …

[ 18 F]-AV-1451 is a leading tracer used with positron emission tomography (PET) to quantify
tau pathology. However, [ 18 F]-AV-1451 shows “off target” or non-specific binding, which …

The recent development of tau-specific positron emission tomography (PET) tracers enables
in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's …

The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET
radioligand 18 F-AV-1451 in cognitively healthy control (HC) and Alzheimer disease (AD) subjects…

Although beta-amyloid (Aβ) deposition is a characteristic feature of Alzheimer's disease (AD),
this pathology is commonly found in elderly normal controls (NC). The pattern of Aβ …

We report the results of a long-term follow-up of subjects in a phase 1 study of AAV2-hAADC
(adeno-associated virus type 2–human aromatic L-amino acid decarboxylase) gene …

The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is important
for Alzheimer disease research and clinical trials but poses several unique challenges. In …